Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
You can find detailed information on this in the following privacy policy
However, we currently have very little data on how much of these medicines pass into breastmilk, or whether they cause side effects in breastfed children
Absolute Contraindications BPC-157 is not recommended for patients with: Active cancer (any type) theoretical concern regarding angiogenesis promotion Pregnancy or breastfeeding insufficient safety data Known hypersensitivity to any component of the formulation Relative Contraindications (Require Individualized Assessment) History of cancer after completion of treatment, a waiting period and oncology clearance may be appropriate Autoimmune disease especially if active or requiring immunosuppressive therapy Anticoagulant use injection site bleeding risk, though minimal with proper technique Severe renal or hepatic impairment dosing adjustments may be needed Monitoring and Follow-Up Patients on BPC-157 protocols are monitored through: Baseline and follow-up labs including inflammatory markers (CRP, ESR), complete blood count, and metabolic panel Clinical assessments pain scores, range of motion, functional outcomes at 2-week, 4-week, and 8-week intervals Imaging when indicated repeat ultrasound or MRI for musculoskeletal conditions to document structural healing The Patient Journey: What to Expect For patients considering peptide therapy, understanding the timeline of response helps set realistic expectations
* Wilding JPH, et al
Canada: Permitted as an ingredient in natural health products (NHPs) under Health Canadas NPN licensing system
By product type, the GLP-1 receptor agonists segment held the largest market share in 2025 and is expected to grow at the fastest CAGR during the projection period
US$ 22.22
US$ 22.47
US$ 23.62
